Alcon

We recently announced our Q4 and full-year 2024 earnings, with strong top-line growth that reinforces our position as the global leader in eye care. These results reflect the strength of our innovation, the dedication of our associates, and the power of our purpose to help people everywhere #SeeBrilliantly. Looking ahead to the next phase of growth in 2025, we remain equally focused on efficiency and quality as we continue to launch our latest innovations to the global eye care market. Learn more: http://spr.ly/6049LXTc3 #Alcon #Earnings

Alcon India is honored to be named among the Top 20 Workplaces in Pharmaceuticals, Healthcare, and Biotech for the second consecutive year. This achievement underscores our unwavering commitment to fostering an outstanding associate experience. Our team’s dedication to creating a culture of trust, innovation, and growth is integral to our purpose to help people #SeeBrilliantly. #AlconIndia

Alcon is thrilled to introduce SYSTANE® PRO Preservative-Free (PF) in the U.S., the latest innovation in our dry eye portfolio. SYSTANE PRO PF is a long-lasting formula that provides dry eye relief. It is an over-the-counter, triple action, preservative-free formula with hyaluronate, nano-sized lipids, HP-Guar and the active ingredient propylene glycol. One of the most common ocular surface disorders, dry eye affects an estimated 1.5 billion people worldwide.¹ Patients can experience a drop that works to provide sustained hydration, restore tear film stability, and protect against further irritation of dry eyes. Learn more: https://lnkd.in/dZgtgn-B Join us at the SECO International meeting in Atlanta, GA, to learn more about the newest addition to Alcon’s SYSTANE family of products. #SystanePRO #Alcon 1. 2023 Dry Eye Products Markets Report, Market Scope, 2023.

The future of first-line glaucoma care has arrived.¹ Alcon is excited to announce the U.S. launch of Voyager™ DSLT, debuting at the American Glaucoma Society annual meeting on February 27. Voyager DSLT is an innovative, first-of-its-kind technology, designed for an exceptional patient and physician experience.¹ Voyager DSLT is fully automated, efficiently lowering intraocular pressure for patients with glaucoma and ocular hypertension.¹ Learn more: http://spr.ly/6042I2NUA #UnlockFirstLine #Glaucoma #VoyagerDSLT 1. GLAUrious Study - Clinical Study Report (CSR). CA-RP-01-006, Rev. 01; 2022.

#BlackHistoryMonth is a time to celebrate the achievements and contributions of the Black community, but it is also a moment to reflect on health disparities that persist in our world. One area that demands attention is the disproportionate burden of eye disease among African Americans. These disparities stem from a combination of genetic factors, differences in ocular anatomy, and access to healthcare. Let’s use this month to recognize these challenges and take steps toward a future where all people can #SeeBrilliantly. References: 1. Glaucoma Facts and Stats | http://spr.ly/6044IWBJe. (2024, November 8). http://spr.ly/6045IWBJ5 2. Diabetes Care 2012;35(3):556–564 http://spr.ly/6046IWBJg

In honor of Black History Month, we’re spotlighting African American leaders who have made a profound impact in eye care. We spoke with Dr. Chandra Mickles, Dr. Leon Herndon, and Dr. Constance Okeke to ask that they share what this month means to them. Their words highlight the importance of representation, and the impact of inspiring future generations. Swipe through to hear their perspectives. #BlackHistoryMonth #Alcon #SeeBrilliantly

Alcon is proud to be named a Top Employer in Europe for the fifth consecutive year. From empowering our associates with meaningful work and development opportunities, to fostering a culture of belonging, this recognition reflects our unwavering commitment to providing an exceptional work environment. To view open roles or join our talent community, visit Alcon.com/careers. #TopEmployerEurope #Alcon #ForABetterWorldOfWork

In honor of International Day of Women and Girls in Science, we asked four incredible women at Alcon what inspires them in their scientific careers. Their stories highlight passion, perseverance, and the power of representation in STEM. Swipe through to hear their insights and join us in honoring the women who are driving innovation at Alcon and making a brilliant impact every day. #IDWGS #Alcon #SeeBrilliantly

Join us in honoring a true visionary in glaucoma care. Congratulations to Michael Belkin, MA, MD, recipient of the Glaucoma Research Foundation Glaucoma 360 Visionary Award, for his groundbreaking contributions to vision science and surgical innovation. Dr. Belkin’s innovative DSLT device will be instrumental in expanding first-line glaucoma care.¹ Dr. Belkin’s many inventions continue to transform lives and help people #SeeBrilliantly. #Alcon #Glaucoma360 #UnlockFirstLine 1. GLAUrious Study - Clinical Study Report (CSR). CA-RP-01-006, Rev. 01; 2022.

At Alcon, research and development is the foundation of how we improve people’s lives. Armed with some of the best and brightest scientific minds, we strive to innovate boldly to fulfill unmet patient needs. The R&D process of our latest contact lens innovation, PRECISION7®, was no exception. Hear from Dr. Steve Zhang, architect of PRECISION7, on how his team pushed boundaries to create the technology behind the one-week replacement lens: https://lnkd.in/dng28HCf #Alcon #Innovation